Expertise in
14
conditions

Dr. William A. Conkright

Hematology | Oncology
Thedacare Regional Medical Center-Appleton Inc.
2500 E Capitol Dr, 
Appleton, WI 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
14
conditions
Thedacare Regional Medical Center-Appleton Inc.
2500 E Capitol Dr, 
Appleton, WI 

Overview

William Conkright is a Hematologist and an Oncologist practicing medicine in Appleton, Wisconsin.

Dr. Conkright is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Schnitzler Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), Immune Thrombocytopenic Purpura (ITP), and Adult Immune Thrombocytopenia.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 15 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in TN

Hospital Affiliations

Bozeman Health Deaconess Hospital
St James Hospital
Livingston Healthcare
Madison Valley Medical Center
Barrett Hospital & Healthcare

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Common Ground Healthcare
  • OTHER COMMERCIAL
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
PacificSource
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Thedacare Regional Medical Center-Appleton Inc.
2500 E Capitol Dr, Appleton, WI 54911

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cabozantinib S-malate, Docetaxel, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab
Study Phase: Phase 2
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 27, 2026
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
View 9 Less Clinical Trials

3 Total Publications

Reply to The effects of curative-intent cancer therapy on employment, work ability, and work limitations.
Reply to The effects of curative-intent cancer therapy on employment, work ability, and work limitations.
Journal: Cancer
Published: March 03, 2021
Similar Doctors
Expertise in
28
conditions
Dr. Ryan H. Engel
Oncology | Hematology
Expertise in
28
conditions
Dr. Ryan H. Engel
Oncology | Hematology
Referral may be required
Before you request

ThedaCare Regional Medical Center Appleton Inc

2500 E Capitol Dr., 
Appleton, WI 
 (0.1 miles away)
Languages Spoken:
English, Italian, Spanish
See accepted insurances
Accepting New Patients

Ryan Engel is an Oncologist and a Hematologist practicing medicine in Appleton, Wisconsin. Dr. Engel is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Small Cell Lung Cancer (SCLC), Inflammatory Breast Cancer, and Paget Disease of the Breast. Dr. Engel is board certified in American Board Of Internal Medicine, Hematology, American Board Of Internal Medicine (2007), Internal Medicine, American Board Of Internal Medicine (2003), and Medical Oncology, American Board Of Internal Medicine (2007). Dr. Engel is currently accepting new patients.

Expertise in
50
conditions
Dr. Michael P. Mullane
Hematology | Oncology
Expertise in
50
conditions
Dr. Michael P. Mullane
Hematology | Oncology
Referral may be required
Before you request

Aurora BayCare Medical Center

2845 Greenbrier Rd, 
Green Bay, WI 
 (24.5 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Mullane is a Hematologist and an Oncologist practicing medicine in Green Bay, Wisconsin. Dr. Mullane is highly rated in 50 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Pleuropulmonary Blastoma, and Monoclonal Gammopathy of Undetermined Significance (MGUS). Dr. Mullane is board certified in American Board Of Internal Medicine, Hematology. Dr. Mullane is currently accepting new patients.

Expertise in
18
conditions
Dr. Tracy J. Miles
Oncology | Hematology
Expertise in
18
conditions
Dr. Tracy J. Miles
Oncology | Hematology
Referral may be required

ThedaCare Cancer CareNeenah

130 Second Street, 
Neenah, WI 
 (8.5 miles away)
920-364-3600
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients

I believe in treating patients with the same care and respect that I would offer my family members. I recognize the unique challenges and needs each patient faces.What I like most about my job is interacting with patients and their family members. I have a passion for building relationships, providing support, empowering patients, continuous learning and making a meaningful difference in the lives of others.I chose to work in oncology because I enjoy providing both medical expertise and emotional support. I enjoy being there for my patients during challenging times, offering comfort, reassurance and guidance. Dr. Miles is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Paget Disease of the Breast, and Breast Cancer. Dr. Miles is board certified in Medical Oncology, American Board Of Internal Medicine (2013) and Internal Medicine, American Board Of Internal Medicine (2007). Dr. Miles is currently accepting new patients.

Frequently Asked Questions about Dr. William A. Conkright

How do I make an appointment with Dr. William A. Conkright?

You can book an appointment with Dr. William A. Conkright by calling their office at 920-749-1171. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. William A. Conkright a top-rated expert for Schnitzler Syndrome?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. William A. Conkright is classified as an Advanced expert for Schnitzler Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. William A. Conkright specialize in?

While Dr. William A. Conkright is a Hematology, they have specific expertise in Schnitzler Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Immune Thrombocytopenic Purpura (ITP). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. William A. Conkright participate in research or clinical trials?

Yes. Dr. William A. Conkright has published 3 articles and abstracts on conditions like Schnitzler Syndrome. You can view a list of Dr. William A. Conkright's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. William A. Conkright accept my insurance?

Dr. William A. Conkright accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 920-749-1171 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Conkright's expertise for a condition
ConditionClose
      View All 14 Advanced Conditions
      View All 137 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile